

# Sylvia Mahara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1082056/publications.pdf>

Version: 2024-02-01

8  
papers

406  
citations

1478280

6  
h-index

1719901

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

748  
citing authors

#	ARTICLE	IF	CITATIONS
1	MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase. <i>Molecular Cell</i> , 2022, 82, 123-139.e7.	4.5	17
2	Genome-scale CRISPR-Cas9 screen of Wnt/ $\beta$ -catenin signaling identifies therapeutic targets for colorectal cancer. <i>Science Advances</i> , 2021, 7, .	4.7	28
3	Targeting the seeds of small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 113-113.	0.7	0
4	Molecular switch of EZH2 in hypoxia. <i>Cell Cycle</i> , 2016, 15, 3007-3008.	1.3	6
5	HIF1 $\alpha$ activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3735-44.	3.3	62
6	The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. <i>Molecular Cancer</i> , 2012, 11, 72.	7.9	29
7	The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. <i>Blood</i> , 2011, 118, 2830-2839.	0.6	205
8	PRL-3, a Metastasis Associated Tyrosine Phosphatase, Is Involved in FLT3-ITD Signaling and Implicated in Anti-AML Therapy. <i>PLoS ONE</i> , 2011, 6, e19798.	1.1	59